Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Long-term efficacy and safety of adjunctive extended-release oxcarbazepine (Oxtellar XR® ) in adults with partial-onset seizures.

Chung SS, Johnson JK, Brittain ST, Baroldi P.

Acta Neurol Scand. 2016 Feb;133(2):124-130. doi: 10.1111/ane.12467. Epub 2015 Aug 6.

2.

Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist.

Ogilvie BW, Torres R, Dressman MA, Kramer WG, Baroldi P.

J Clin Pharmacol. 2015 Sep;55(9):1004-11. doi: 10.1002/jcph.507. Epub 2015 May 7.

PMID:
25851638
3.

Absolute Bioavailability of Tasimelteon.

Torres R, Dressman MA, Kramer WG, Baroldi P.

Am J Ther. 2015 Sep-Oct;22(5):355-60. doi: 10.1097/MJT.0000000000000195.

PMID:
25658956
4.

Pharmacokinetics of the dual melatonin receptor agonist tasimelteon in subjects with hepatic or renal impairment.

Torres R, Kramer WG, Baroldi P.

J Clin Pharmacol. 2015 May;55(5):525-33. doi: 10.1002/jcph.440. Epub 2015 Feb 4.

5.

Efficacy and safety of extended-release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial-onset seizures: a randomized controlled trial.

French JA, Baroldi P, Brittain ST, Johnson JK; PROSPER Investigators Study Group.

Acta Neurol Scand. 2014 Mar;129(3):143-53. doi: 10.1111/ane.12207. Epub 2013 Dec 21.

6.

A phase 2a randomized, parallel group, dose-ranging study of molindone in children with attention-deficit/hyperactivity disorder and persistent, serious conduct problems.

Stocks JD, Taneja BK, Baroldi P, Findling RL.

J Child Adolesc Psychopharmacol. 2012 Apr;22(2):102-11. doi: 10.1089/cap.2011.0087. Epub 2012 Feb 28.

PMID:
22372512
7.

Effects of oral and intravenous terazosin and head-up tilt on blood pressure responses in patients with hypertension.

Achari R, Hosmane B, Linnen P, Cavanaugh J, Baroldi P, Cohen A.

J Clin Pharmacol. 1998 Jun;38(6):545-53.

PMID:
9650545
8.

Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir.

Hsu A, Granneman GR, Cao G, Carothers L, el-Shourbagy T, Baroldi P, Erdman K, Brown F, Sun E, Leonard JM.

Clin Pharmacol Ther. 1998 Apr;63(4):453-64.

PMID:
9585800
9.

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.

Kempf DJ, Marsh KC, Kumar G, Rodrigues AD, Denissen JF, McDonald E, Kukulka MJ, Hsu A, Granneman GR, Baroldi PA, Sun E, Pizzuti D, Plattner JJ, Norbeck DW, Leonard JM.

Antimicrob Agents Chemother. 1997 Mar;41(3):654-60.

10.

Evaluation of personality as a component of the healthy condition of volunteers participating in phase I studies.

Berto D, Milleri S, Squassante L, Baroldi PA.

Eur J Clin Pharmacol. 1996;51(3-4):209-13.

PMID:
9010686
11.

A study of plasma disposition kinetics of lacidipine after single oral ascending doses.

Squassante L, Caveggion E, Braggio S, Pellegatti M, Baroldi P.

J Cardiovasc Pharmacol. 1994;23 Suppl 5:S94-7.

PMID:
7609516
12.

Relief of pain following intravesical capsaicin in patients with hypersensitive disorders of the lower urinary tract.

Barbanti G, Maggi CA, Beneforti P, Baroldi P, Turini D.

Br J Urol. 1993 Jun;71(6):686-91.

PMID:
8343895
13.

Autoradiographic localization of octylonium bromide binding sites in the rat gastrointestinal tract.

Amenta F, Baroldi P, Ferrante F, Napoleone P, Meli A.

Arch Int Pharmacodyn Ther. 1991 May-Jun;311:5-19.

PMID:
1724144
14.

Venous blood platelets decrease during allergen-induced asthmatic reactions.

Maestrelli P, Boschetto P, Zocca E, Crescioli S, Baroldi P, Mapp C, Fabbri LM.

Clin Exp Allergy. 1990 Jul;20(4):367-72.

PMID:
2198085
15.

Immunoblockade by a specific tachykinin antiserum of the non-cholinergic contractile responses in the guinea-pig isolated bronchus.

Maggi CA, Patacchini R, Baroldi P, Theodorsson E, Meli A.

J Auton Pharmacol. 1990 Jun;10(3):173-9.

PMID:
1696261
16.

Octylonium bromide interacts competitively with the PAF receptor.

Barone D, Maggi CA, Baroldi P, Giachetti A, Meli A.

Drugs Exp Clin Res. 1989;15(8):363-7.

PMID:
2557193
17.

Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients.

Mattei AM, Ferrari C, Baroldi P, Cavioni V, Paracchi A, Galparoli C, Romano C, Spellecchia D, Gerevini G, Crosignani PG.

J Clin Endocrinol Metab. 1988 Jan;66(1):193-8.

PMID:
3275684
18.

Inhibition of basal and metoclopramide-induced prolactin release by cabergoline, an extremely long-acting dopaminergic drug.

Pontiroli AE, Cammelli L, Baroldi P, Pozza G.

J Clin Endocrinol Metab. 1987 Nov;65(5):1057-9.

PMID:
3667876
19.

Dose-related prolactin inhibitory effect of the new long-acting dopamine receptor agonist cabergoline in normal cycling, puerperal, and hyperprolactinemic women.

Melis GB, Gambacciani M, Paoletti AM, Beneventi F, Mais V, Baroldi P, Fioretti P.

J Clin Endocrinol Metab. 1987 Sep;65(3):541-5.

PMID:
3624413

Supplemental Content

Loading ...
Support Center